The effect of exercise and spirulina supplementation on the Asprosin hormone in overweight me

Not Applicable

• Conditions: Overweight and obesity.; Overweight and obesity

• Registration Number: IRCT20160813029322N4
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 60

Inclusion Criteria

Aged between 50-30 years old
General physical and mental health
Body mass index (BMI) more than 25 kg / m 2

Exclusion Criteria

If the participant has exercised regularly during 6 months before the start of training sessions
If the participant has suffers from cardiovascular diseases
If the participant has suffers from diabetes disease
If the participant has suffers from hormonal disorders disease
If the participant has suffers from kidney disease
If the participant has suffers from liver disease
If the participant is a smoker
If the participant has recently had any surgery or medical interventions

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Asprosin. Timepoint: Before the intervention and two months after the intervention. Method of measurement: Plasma Asprosin levels were measured using an ELISA kit (Zell Bio Co made in Germany with a sensitivity of 0.05 ng/m), and ELISA-by-ELISA Reader (US lotion model).;Glucose. Timepoint: Before the intervention and two months after the intervention. Method of measurement: ParsAzmon Kit (mg/dl).;Triglyceride. Timepoint: Before the intervention and two months after the intervention. Method of measurement: ParsAzmon Kit (mg/dl).;Cholesterol. Timepoint: Before the intervention and two months after the intervention. Method of measurement: ParsAzmon Kit (mg/dl).;High Density Lipoprotein. Timepoint: Before the intervention and two months after the intervention. Method of measurement: ParsAzmon Kit (mg/dl).;Low Density Lipoprotein. Timepoint: Before the intervention and two months after the intervention. Method of measurement: ParsAzmon Kit (mg/dl).

Secondary Outcome Measures

Name	Time	Method
east body mass. Timepoint: Before the intervention and two months after the intervention. Method of measurement: Body composition analyzer, model IOI 353, made by Jawon Medical, South Korea.;Lean body mass. Timepoint: Before the intervention and two months after the intervention. Method of measurement: Body composition analyzer, model IOI 353, made by Jawon Medical, South Korea.;Waist to height ratio. Timepoint: Before the intervention and two months after the intervention. Method of measurement: Height will be measured with Sahand Company's height meter and Waist circumference will be measured with a Tape meter (made in Iran).